A genome-wide siRNA screen on patient-derived Fanconi anemia pathway-deficient head-and-neck squamous-cell-carcinoma (HNSCC) cell lines identifies RBBP9 as a candidate therapeutic target. Here, RBBP9 is linked to Fanconi anemia.